P
Protai Bio
Illuminating the druggable Proteome for better cures
About Protai Bio
Protai.bio is a cutting-edge biotech startup that operates at the intersection of proteomics and machine learning. Proteomics is the large-scale study of proteins, which are vital parts of living organisms and perform a vast array of functions. By leveraging the latest advances in this field, along with machine learning, Protai.bio is able to simulate diseases at the molecular level. This deep understanding of protein networks allows the company to precisely target complex disease drivers, which could potentially revolutionize the way diseases are treated.
Read full description
The company's primary offering is a proteomics-centered, vertically integrated platform designed for drug discovery. This platform is disease- and modality-agnostic, meaning it can be used to study any disease and is not limited to a specific method or approach. The platform covers everything from data collection to target identification and drug discovery, providing a comprehensive solution for pharmaceutical research.
Protai.bio's business model revolves around collaborations with leading pharmaceutical companies and academic labs. By partnering with these entities, the company is able to apply its technology to real-world problems and contribute to the development of new treatments. This collaborative approach not only allows Protai.bio to generate revenue, but also positions it as a key player in the future of medicine.
In summary, Protai.bio is a biotech startup that uses proteomics and machine learning to simulate diseases at the molecular level, with the aim of aiding drug discovery. Its business model is based on collaborations with pharmaceutical companies and academic labs.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 83.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Biotech and Pharma, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Mar 2023 | $12M | $48M | Maj Invest · Pitango Venture Capital · Grove Ventures | ↗ |
| SEED✓Equity / VC | Jan 2022 | $8M | $32M | Pitango Venture Capital · Grove Ventures | ↗ |
Growth signals
Latest recorded traffic for Protai Bio is 2.7K monthly website visits, up 2600% over the last three months. Protai Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Pitango Venture Capital
Grove Ventures
Maj Invest
Other known investors1 additional known investor
Endless Frontier Labs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Protai Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Protai Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.